Albert Bourla
Showing 1–2 of 2 transcripts.
- Lex Fridman1h 8m
Albert Bourla: Pfizer CEO | Lex Fridman Podcast #249
Host Alex Friedman engages Pfizer CEO Albert Bourla to dismantle pandemic-era polarization by detailing the company's $2.3 billion strategic gamble and the rigorous, transparent regulatory processes that secured global approval for its vaccines. Bourla clarifies the scientific realities behind the record-breaking development timelines, addresses controversies regarding data transparency and workforce mandates, and outlines Pfizer's capacity to rapidly adapt manufacturing for future variants or new antiviral therapies like Paxlovid. Through this dialogue, the discussion moves beyond conspiracy theories to focus on the intersection of high-stakes financial investment, strict safety protocols, and the human imperative to bridge trust gaps through empathetic science communication.
- Milken Institute1h 2m
In Search for a Cure: Are We Nearing a Treatment for COVID-19?
Esther Kofa, Meg Terrell, Dr. Tony Fauci, Albert Bourla
The Milken Institute Summer Series concluded by analyzing the U.S. resurgence of COVID-19 infections and the global development of nearly 250 treatment compounds, featuring critical insights from Dr. Anthony Fauci and Pfizer CEO Dr. Albert Bourla. Dr. Fauci warned of severe fall surges driven by behavioral shifts while outlining a vaccine timeline with Phase III trials expected to begin in July, whereas Dr. Bourla detailed Pfizer's autonomous mRNA strategy aiming for safety and efficacy data by September. As the organization prepares its 23rd Global Conference for a likely online format in October, these discussions underscored the urgent need for robust public health protocols alongside rapid medical solutions.